MA50511A - Traitement de la schizophrénie - Google Patents

Traitement de la schizophrénie

Info

Publication number
MA50511A
MA50511A MA050511A MA50511A MA50511A MA 50511 A MA50511 A MA 50511A MA 050511 A MA050511 A MA 050511A MA 50511 A MA50511 A MA 50511A MA 50511 A MA50511 A MA 50511A
Authority
MA
Morocco
Prior art keywords
schizophrenia
treatment
Prior art date
Application number
MA050511A
Other languages
English (en)
Inventor
Armida Mucci
Françoise Tonner
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA50511A publication Critical patent/MA50511A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA050511A 2017-11-03 2018-11-05 Traitement de la schizophrénie MA50511A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762581249P 2017-11-03 2017-11-03

Publications (1)

Publication Number Publication Date
MA50511A true MA50511A (fr) 2020-09-09

Family

ID=64402162

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050511A MA50511A (fr) 2017-11-03 2018-11-05 Traitement de la schizophrénie

Country Status (11)

Country Link
US (2) US10842789B2 (fr)
EP (1) EP3703695B1 (fr)
JP (1) JP7250787B2 (fr)
KR (1) KR20200083978A (fr)
CN (1) CN111295191A (fr)
AU (1) AU2018360298A1 (fr)
BR (1) BR112020007573A2 (fr)
CA (1) CA3079994A1 (fr)
MA (1) MA50511A (fr)
MX (1) MX2020004443A (fr)
WO (1) WO2019086661A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663638B2 (fr) 1990-04-06 1995-02-10 Institut Nal Sante Recherc Medic Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques

Also Published As

Publication number Publication date
MX2020004443A (es) 2020-11-24
JP2021501775A (ja) 2021-01-21
US10842789B2 (en) 2020-11-24
CN111295191A (zh) 2020-06-16
CA3079994A1 (fr) 2019-05-09
EP3703695B1 (fr) 2022-12-21
AU2018360298A1 (en) 2020-04-23
WO2019086661A1 (fr) 2019-05-09
EP3703695A1 (fr) 2020-09-09
JP7250787B2 (ja) 2023-04-03
KR20200083978A (ko) 2020-07-09
BR112020007573A2 (pt) 2020-09-24
US20190134026A1 (en) 2019-05-09
US20200383976A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA43190A (fr) Traitement de la dyslipidémie mixte
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA41449A (fr) Polythérapies pour le traitement de cancers
DK3851537T3 (da) Behandling af hyperbilirubinæmi
MA47719A (fr) Esketamine pour le traitement de la dépression
IL268694A (en) Treatment of schizophrenia
MA47820A (fr) Traitement de la glycogénose de type iii
MA46361A (fr) Traitement du cancer de la prostate
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA42999A (fr) Polythérapie pour le traitement de malignités
DK3307267T3 (da) Behandling af multipel sklerose
MA49059A (fr) Traitement des cancers positifs à her2
MA47408A (fr) Traitement du cancer
DK3548061T3 (da) Behandling af neurologiske sygdomme
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
MA42930A (fr) Traitement de maladies neurodégénératives
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA51525A (fr) Traitement de minéraux
MA41490A (fr) Procédé de prévention ou de traitement de la perte auditive
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
FR3039368B1 (fr) Procede de traitement cosmetique